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Summary Intertemporal choices between a smaller sooner and a larger delayed reward are one
of the most important types of decisions humans face in their everyday life. The degree to which
individuals discount delayed rewards correlates with impulsiveness. Steep delay discounting has
been associated with negative outcomes over a wide range of behaviors such as addiction.
However, little is known about the biological foundations of delay discounting. Here, we examine
a potential causal link between delay discounting and testosterone, a hormone which has been
associated with other types of impulsive behavior. In our double-blind placebo-controlled study
91 healthy young men either received a topical gel containing 50 mg of testosterone (N = 46) or a
placebo (N = 45) before participating in a delay discounting task with real incentives. Our main
finding is that a single dose administration of testosterone did not lead to significant differences in
discount rates between the placebo and the testosterone group. Within groups and in the pooled
sample, no significant relationship between testosterone and discount rates was observed. At the
same time, we do replicate standard findings from the delay discounting literature such as a
magnitude-of-rewards effect on discount rates. In sum, our findings suggest that circulating
testosterone does not have a significant effect on delay discounting in young men.
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Time preferences are a fundamental building block of human
behavior. Many decisions humans face involve intertemporal
trade-offs, in which present goods have to be weighed
against future goods. Typically, rewards to be received in
the future are valued less than rewards of equal size received
today (Frederick et al., 2002). Delay discounting refers to the
subjective depreciation of rewards received in the future,
where the depreciation increases with the delay of receiving
the reward. The discount rate k captures the rate at which
this depreciation occurs, low k individuals are thus more
willing to delay gratification. Individual discount rates vary
substantially and have been proposed as a measure of impul-
siveness (Kirby et al., 1999). Higher discount rates have been
associated with unfavorable outcomes in a wide range of
important dimensions including substance abuse (e.g. Kirby
et al., 1999) and gambling (Dickson et al., 2003).
Little is known, however, about the sources of hetero-
geneity in delay discounting. Recent evidence suggests the
hormone testosterone may lead to steeper discounting of the
future. Several studies reported a positive correlation
between circulating levels of testosterone and other types
of impulsive behavior, e.g., in the IOWA gambling task (Van
Honk et al., 2004), or the ultimatum game (Burnham, 2007).
In addition, two recent studies found that exposure to sexual
cues induced men to discount the future steeper (Wilson and
Daly, 2004; van den Bergh et al., 2008). Elevated testoster-
one levels in response to sexual cues could be one underlying
reason for the higher discount rates (Lucas and Koff, 2010).
Only one study investigated a potential correlation of endo-
genous testosterone levels and delay-discounting of
(hypothetical) rewards (Takahashi et al., 2006). This study
found a significant non-linear relationship between endogen-
ous salivary testosterone level and discount rate, i.e., a
positive correlation for individuals with a low k and a nega-
tive correlation for individuals with a high k. However, due to
potential behavior-hormone feedback this type of evidence
precludes causal inference. To date no study investigating a
causal link between testosterone and delay discounting
exists. We therefore conducted a double-blind placebo con-
trolled experiment with real incentives to study the effect of
a single dose administration of testosterone on delay dis-
counting. More specifically, we tested the hypothesis that
testosterone leads to steeper discounting of the future, i.e.,
a higher discount factor k.
2. Materials and methods
2.1. Subjects
91 healthy men (age 24.32  2.73 years) gave written
informed consent prior to participation in the study. Subjects
were recruited via the volunteer database of the BonnEcon-
Lab and through posters on campus. Before deciding whether
to participate subjects could visit a website with information
about the experiment (timing, payment, side effects, exclu-
sion criteria). All subjects were screened to exclude benign
prostate hypertrophy, prostate cancer, heart failure, renal
failure, hepatic failure, epilepsy or migraine history, and
exogenous uptake of cortisone or ACTH. No adverse eventsoccurred. The study was approved by the ethics committee of
the medical department of the University of Bonn.
2.2. Measuring individual discount rates
We used the well-established monetary choice questionnaire
(Kirby et al., 1999) to elicit individual discount rates. In this
delay discounting task subjects have to make 27 consecutive
choices between a smaller immediate reward (SIR, range:
11—80 euro) and a larger delayed reward (LDR, range: 25—
85 euro) to be received in X days (range: 7—186 days).
Questions had the following form: ‘‘Which payment do you
prefer—SIR today or LDR in X days?’’ Subjects had an incentive
to respond truthfully since there was a 1-in-6 chance that one
of the 27 decisions was randomly chosen and actually paid.
Dollar amounts from Kirby et al. (1999) were converted into
Euro at a rate of 1:1. Assuming a hyperbolic discounting
function V = A/(1 + kD), where V is the present value of
the delayed reward A at delay D, a value of k, at which
the immediate reward is equal to the discounted delayed
reward can be determined for each of the 27 choices. In our
case, k assumes 9 different values ranging from 0.00016 to
0.25. For each value of k, there are three different versions
of a question using different reward sizes (small, medium,
and large) in order to assess potential effects of reward size
on delay discounting. Estimation of the discount rate k
follows the procedure described in Kirby et al. (1999). We
estimate the discount rate k for every individual by deter-
mining the switching point at which an individual begins to
prefer larger, delayed rewards over smaller, immediate
rewards for each of the three reward sizes. We obtained
the overall discount rate k for every individual by taking the
geometric mean of the ks for the different reward sizes.
2.3. Experimental procedure
The study used a double-blind, placebo-controlled design.
There was no deception in any part of the experiment. Each
session of the study took place on two consecutive days. On day
1, subjects reported individually to the Institute for Empirical
Research in Economics at the University of Bonn between
10 am and 1 pm. After receiving general instructions, subjects
were randomly assigned to the testosterone or the placebo
group and a medical research assistant applied a topical gel
containing 50 mg of testosterone (Testogel1, Jenapharm
GmbH&Co. KG, Jena, Germany) or a placebo gel on their upper
right arm (Testosterone: N = 46; Placebo: N = 45). Afterwards
participants had to wait until the gel was fully absorbed
(approx. 10 min) before leaving the institute. Subjects were
asked to refrain from showering or swimming for at least 6 h
after the transdermal application, to avoid drinking alcohol
until the end of the experiment and to obtain enough sleep.
The testosterone was allowed to load for 21—24 h prior to the
decision task. On day 2 subjects reported to the BonnEconLab
at 10 am to participate in the discounting task described above
and several unrelated experiments. They were seated in
separate cubicles closed off with curtains and read self-paced
instructions for the experiments. All experiments were pro-
grammed with ztree (Fischbacher, 2007).
After the experiments, a blood sample was taken from
each subject in a separate room before they received their
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the reward was mailed to the subject one day before the
agreed day given that most letters in Germany reach their
destination over night. The sessions on day 2 lasted on
average 150 min including blood sampling and payment pro-
cedures.
2.4. Testosterone measurement
The blood samples were stored at the hormone laboratory of
the gynecologic clinic at the University of Bonn and processed
within a day after collection for measurement of total
testosterone using a one-step Chemieluminescent Microppar-
ticle Immunoassay (ARCHITECT Testosterone, Abbott Labora-
tories, Wiesbaden, Germany). The intraassay and the
interassay coefficients were 1.9% and 3.7% respectively, with
a lower detection limit of 0.14 ng/ml.
2.5. Questionnaires
After the experiment, subjects answered several question-
naires on socio-demographic characteristics and personality
variables. For a subset of subjects (N = 51) we also elicited at
the end of the questionnaires whether they believed they had
received testosterone or placebo.
2.6. Statistical analysis
Non-parametric Mann—Whitney U-tests were used to test
for differences in discount rates between the two groups.
Friedman tests were used to test whether discount rates
depended on reward size. Post hoc analysis for these tests
was carried out using Wilcoxon Signed Rank tests with Bon-
ferroni correction for multiple comparisons. Spearman rank
order correlations were used to test for associations
between testosterone level and discount rates. A Chi2 test
was used to test for an association of actual and perceivedFigure 1 Frequency of discount rates in the placebo and the tes
questionnaire.testosterone administration. All tests are two-tailed. Ordin-
ary least square regressions with log-normalized ks were
used to replicate the analyses in Takahashi et al. (2006).
3. Results
3.1. Testosterone levels
In the treatment group the mean level of testosterone was
7.78  2.07 ng/l, compared to 6.79  2.04 ng/l in the con-
trol group. The difference between the two groups is sig-
nificant ( p < 0.05, two-sample U-test). There was no
correlation between actual and perceived testosterone
administration (Pearson’s Chi2 test, p = 0.94).
3.2. Discount rates
Subjects in the treatment group had a mean discount rate k of
0.0295  .0468, while the mean k was 0.0203  .0254 in the
control group (Fig. 1). The difference in discount rates
between the two treatment groups is not statistically sig-
nificant ( p = 0.538, two-sample U-test). We also do not find a
significant difference in discount rates between the two
treatments for any of the three different reward size cate-
gories (two sample U-tests, all p > 0.525). We also tested for
a correlation between testosterone levels and discount rates
in the pooled sample, and separately for each treatment. In
contrast to our hypothesis, the correlation coefficients are
negative and none of these correlations is significant (Spear-
man correlation, pooled: r = 0.15, p = 0.149; placebo:
r = 0.10, p = 0.500; testosterone: r = 0.17, p = 0.256.).
The same result holds when testing for correlations in the
different reward size categories separately.
In line with previous studies (e.g. Kirby et al., 1999), we do
find a magnitude effect on discount rates in both treatments
(Friedman test, placebo: x(2) = 15.83, p < 0.001; testoster-
one: x(2) = 19.70, p < 0.001). Post hoc analysis withtosterone group for the ranges defined by the monetary choice
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significance p = 0.017) revealed higher discount rates for
small and medium delayed rewards compared to large
delayed rewards, but not (or only by trend) for small com-
pared to medium rewards (placebo: small vs. medium:
p = 0.042, medium vs. large p = 0.002; testosterone small
vs. medium: p = 0.026, medium vs. large p < 0.001).
Takahashi et al. (2006) regressed testosterone levels on
ln(k) and ln(k)2 and observed a significant invert U-shaped
relation. We replicate their analysis for our data (OLS
regressions for pooled data and each treatment separately)
but do not find a significant relationship ( p > 0.449 for all
coefficients).
4. Discussion
The present study examined a potential causal link between
circulating testosterone and delay discounting. The main
finding of our placebo-controlled study is that there is no
significant difference in discount rates between the pla-
cebo and the testosterone group. We also did not find any
significant linear or quadratic-relationship between testos-
terone levels and discount rates in either group or the
pooled sample. Our study thus offers no support for the
hypothesis that circulating testosterone influences delay
discounting.
Our study differs from previous testosterone administra-
tion studies on decision making in several methodological
aspects. Most notably, most of these studies use female
samples and sublingual testosterone administration. While
for women an optimal delay between peak serum levels and
behavioral testing of 4 h has been suggested based on neu-
rophysiological evidence (Tuiten et al., 2000), little is known
about the optimal delay between tmax and behavioral testing
in men. The only previous study on the influence of testos-
terone administration on social behavior in men (Zak et al.,
2009) finds a behavioral effect after 16 h. Based on the
pharmacokinetics of testosterone administration using a
topical gel in healthy men (Chik et al., 2006; Eisenegger
et al., 2012) the delay between tmax and behavioral testing in
our study was at least 5—7 h. Methodological differences
compared to those studies reporting positive findings in
other domains of decision making might thus be a potential
alternative explanation for the absence of a treatment
effect.
However, there are several reasons to believe that our
findings are valid. First of all, we do observe a behavioral
effect of testosterone administration in another task played
with the same subjects in the same experimental session
(Wibral et al., 2012). The incidence of self-serving lying in a
die-rolling paradigm is much lower in the testosterone group
compared to the placebo group. Second, our results regard-
ing discount rates are comparable to previous studies. We do
observe the characteristic magnitude effect of rewards in the
testosterone as well as the placebo group. The levels of k
observed in our sample are in line with a previous study also
using a sample of young men (Takahashi et al., 2006). Third,
while it is possible that our sample size is still too small to pick
up an effect, it is substantially larger than samples used in
recent single-dose administration studies on the behavioral
effects of testosterone and the sample which Takahashi et al.(2006) use to investigate the relation between testosterone
and discount rates (N = 75). Finally, we use blood samples for
assessing testosterone levels, which should reduce measure-
ment error (Millet, 2004). While we only measure total
testosterone the findings in Eisenegger et al. (2012) suggest
that testosterone administration also raises free testoster-
one and does not induce secondary changes in SHBG.
An interesting question for further research is whether our
null finding will also hold in a setup in which delay discounting
is relevant for social status. The most convincing evidence for
an influence of testosterone on decision making stems from
situations involving a challenge to social status (Eisenegger
et al., 2011). It is therefore possible that testosterone affects
delay discounting in such a context.
One limitation of the current study is that only male
university students were tested. It is possible that different
results might have been obtained in a female or a more
diverse male sample. It is also possible that cognitive ability
mediates the influence of testosterone on delay discounting.
Higher intelligence has been associated with lower discount
rates (Shamosh and Gray, 2008; Dohmen et al., 2010). One
hypothesis is that intelligence influences the integration of
the appraisal of sooner and later rewards into a decision
(Shamosh and Gray, 2008). On a neural level, delay discount-
ing seems to involve a valuation network including the
orbitofrontal cortex and the ventral striatum, and a cognitive
control network (Peters and Bu¨chel, 2011). Recent evidence
suggests that a higher testosterone level affects activity in
parts of the valuation network in a way that would lead to
steeper discounting (e.g., Hermans et al., 2010). It remains
possible that testosterone influences delay discounting via an
effect on the appraisal of rewards. This effect, however,
could be overridden by the influence of cognitive ability in
our sample of university students with high cognitive ability.
In conclusion, the present study indicates that circulating
testosterone does not have a significant effect on delay
discounting in male university students.
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